Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


12th World Cancer Conference

London, UK

Oana Elena Baran

Oana Elena Baran

University of Medicine and Pharmacy, Romania

Title: Analysis of convergent effects of doxorubicin, quercetin and menadione in treatments of human leukemia Jurkat T cells


Biography: Oana Elena Baran


Given the major diversity of cancer forms, development of treatments with specific functions is of great importance. In this in vitro study, leukemia Jurkat cells interactions with antitumoral antibiotic Doxorubicin (DOX) were investigated, and their modulation by flavonoid Quercetin (QC) and Menadione (MD). Cell cycle, apoptosis/necrosis and oxidative status were assessed by flow cytometry. DOX acts on malignant cells via cell-cycle arrest, mitochondrial depolarisation and oxidative stress. Cellular viabilty dose-dependently decreased after 18 h and 48 h exposure to DOX (IC50=571 nM and 93 nM, respectively), while the sub-G0 cell fraction increased (IC50=385 nM and 128 nM, respectively). Also, 0.1 mM and 1 mM DOX arrested the cell cycle in G2/M (63% cells) and S phase (70%), respectively. In 18 h treatments, the 15 mM equimolar QC/MD combination produced by itself 52% cell death rate, by oxidative stress generation and apoptosis induction, and enhanced DOX cytotoxicity, dramatically decreasing the viable cell fraction (IC50=1.25 mM). 15 mM QC with 7.5 mM MD produced 69% viable cells; association with DOX exhibited additive cytotoxicity (IC50=2.26 mM). 48 h exposures further enhanced the effects. Addition of QC/MD up to 7.5 mM and 2.5 mM, respectively, to the 0.1 mM and 1 mM DOX-plan, increased the S-cell fraction, with higher levels progressively increasing the G0/G1 cell fraction. Therefore, QC/MD combination appears to be a good addition to DOX-treatments.